GlaxoSmithKline Posts $510 Million Net Loss
February 03 2016 - 8:30AM
Dow Jones News
GlaxoSmithKline PLC swung to a net loss in the fourth quarter of
the year even as revenue increased, largely due to restructuring
costs following its three-part transaction with Novartis AG.
The U.K.-based drugmaker said its loss attributable to
shareholders was £ 354 million ($510 million) in the quarter ending
Dec. 31, compared with a £ 1 billion profit a year earlier, while
revenue climbed to £ 6.3 billion from £ 6.2 billion. Core net
profit, which strips out some one-time items, fell 34% to £ 874
million. Analysts had expected revenue of £ 6.3 billion and core
net profit of £ 903 million.
The decline in core net profit was largely down to Glaxo's shift
to a higher-volume, lower-margin business following its $20 billion
asset-swap deal with Novartis. In that deal, which closed in the
first quarter of 2015, Glaxo traded its cancer drugs for the Swiss
company's vaccines business. The pair also formed a joint venture
for their consumer health care businesses which span
over-the-counter drugs, such as painkiller Panadol, as well as
non-pharmaceuticals like toothpaste.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
February 03, 2016 08:15 ET (13:15 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024